Summary
Pfizer Inc. (PFE) filed a Form 8-K on July 21, 2004, to report its financial results for the second quarter of 2004. The filing primarily consists of a press release, which serves as the main source of information regarding the company's performance during the period. Investors should note that this 8-K is a notification of the release of quarterly earnings and directs readers to the press release for the detailed financial and operational data. The press release, incorporated as Exhibit 99, contains Pfizer's financial results for the second quarter ended July 21, 2004. While the 8-K itself does not contain the specific figures, it signifies that Pfizer has disclosed its performance metrics, including revenue, profitability, and potentially other key operational indicators for the quarter. Investors seeking to understand Pfizer's financial health and strategic progress would need to review the accompanying press release.
Key Highlights
- 1Pfizer Inc. (PFE) released its second quarter 2004 financial results on July 21, 2004.
- 2The filing is a Form 8-K, which serves as an official notification of the earnings release.
- 3The detailed financial results are contained within a press release furnished as Exhibit 99 to the 8-K.
- 4The press release includes information on Pfizer's performance for the second quarter of 2004.
- 5This filing is a standard disclosure mechanism for publicly traded companies to announce quarterly earnings.
- 6Investors are directed to the press release for specific financial figures and operational details.